Larimar Therapeutics, Inc.

NasdaqGM:LRMR Stock Report

Market Cap: US$502.1m

Larimar Therapeutics Management

Management criteria checks 3/4

Larimar Therapeutics' CEO is Carole Ben-Maimon, appointed in May 2020, has a tenure of 4.08 years. total yearly compensation is $3.14M, comprised of 17.8% salary and 82.2% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth $889.91K. The average tenure of the management team and the board of directors is 3.9 years and 3.9 years respectively.

Key information

Carole Ben-Maimon

Chief executive officer

US$3.1m

Total compensation

CEO salary percentage17.8%
CEO tenure4.1yrs
CEO ownership0.2%
Management average tenure3.9yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

May 31

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Nov 13
We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

May 19
Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 02
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Laramar Therapeutics issued patent for lead pipeline candidate

Oct 20

Larimar Therapeutics prices ~$70M stock offering

Sep 14

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Sep 02
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Larimar Therapeutics GAAP EPS of -$0.47

Aug 11

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Mar 21
We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Dec 18
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

May 26

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 08
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index

Dec 15

Larimar completes dosing in Friedreich’s Ataxia, provides program update

Dec 08

Larimar Therapeutics (LRMR) Investor Presentation - Slideshow

Nov 16

Larimar Therapeutics reports Q3 results

Nov 10

CEO Compensation Analysis

How has Carole Ben-Maimon's remuneration changed compared to Larimar Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$45m

Dec 31 2023US$3mUS$560k

-US$37m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$2mUS$528k

-US$35m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$47m

Dec 31 2021US$2mUS$510k

-US$51m

Sep 30 2021n/an/a

-US$56m

Jun 30 2021n/an/a

-US$49m

Mar 31 2021n/an/a

-US$48m

Dec 31 2020US$5mUS$268k

-US$42m

Compensation vs Market: Carole's total compensation ($USD3.14M) is about average for companies of similar size in the US market ($USD2.44M).

Compensation vs Earnings: Carole's compensation has increased whilst the company is unprofitable.


CEO

Carole Ben-Maimon (65 yo)

4.1yrs

Tenure

US$3,137,432

Compensation

Dr. Carole S. Ben-Maimon, M.D., is President, Chief Executive Officer and Director at Larimar Therapeutics, Inc. since May 28, 2020. She was Chief Executive Officer, President and Director at Chondrial The...


Leadership Team

NamePositionTenureCompensationOwnership
Carole Ben-Maimon
CEO, President & Director4.1yrsUS$3.14m0.18%
$ 889.9k
Michael Celano
Secretary & CFO4.1yrsUS$1.42m0.087%
$ 438.7k
Gopi Shankar
Chief Development Officer1.3yrsUS$1.43m0.0078%
$ 39.4k
John Berman
Vice President of Finance & Administrationless than a yearno datano data
Jennifer Johansson
Vice President of Legal & Compliance7.5yrsno datano data
Russell Clayton
Chief Medical Officerless than a yearno datano data
Francis Conway
VP & Controller3.9yrsno datano data

3.9yrs

Average Tenure

64yo

Average Age

Experienced Management: LRMR's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Carole Ben-Maimon
CEO, President & Director4.1yrsUS$3.14m0.18%
$ 889.9k
Jonathan Leff
Independent Director4.1yrsUS$79.96kno data
Jeffrey Sherman
Independent Directorless than a yearUS$56.43k0%
$ 0
Frank Thomas
Independent Director10yrsUS$86.21k0.0031%
$ 15.7k
Thomas Hamilton
Independent Director4.1yrsUS$77.77k0.89%
$ 4.4m
Joseph Truitt
Independent Chairman of the Board4.1yrsUS$114.96k0.0043%
$ 21.6k
Giovanni Manfredi
Member of Scientific Advisory Board3.7yrsno datano data
Mark Payne
Member of Scientific Advisory Board3.7yrsno datano data
Marni Falk
Member of Scientific Advisory Board3.7yrsno datano data
Jill Ostrem
Member of Scientific Advisory Board1.8yrsno datano data

3.9yrs

Average Tenure

57.5yo

Average Age

Experienced Board: LRMR's board of directors are considered experienced (3.9 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.